Main One of OSMP’s primary functions is to train and communicate OSMP issues both internally with FDA staff, and externally with the regulated industry. OSMP staff is frequently invited to participate at universities, conferences, workshops, and training sessions. These activities are intended to foster efficiency and innovative product development, expedite the premarket review process, and enhance the safe and ethical development of therapies by increasing understanding and transparency of the complex regulatory issues raised by medical products. <i>Information is current as of December 31, 2012.</i> Number column

FY 2010 Total: 425

Oct 2009 47 Nov 2009 30 Dec 2009 32 Jan 2010 16 Feb 2010 27 Mar 2010 43 Apr 2010 45 May 2010 30 Jun 2010 46 Jul 2010 27 Aug 2010 50 Sep 2010 32

FY 2011 Total: 537

Oct 2010 68 Nov 2010 34 Dec 2010 37 Jan 2011 25 Feb 2011 59 Mar 2011 60 Apr 2011 45 May 2011 37 Jun 2011 37 Jul 2011 28 Aug 2011 41 Sep 2011 66

FY 2012 Total: 406

Oct 2011 50 Nov 2011 23 Dec 2011 28 Jan 2012 24 Feb 2012 26 Mar 2012 39 Apr 2012 30 May 2012 45 Jun 2012 30 Jul 2012 15 Aug 2012 27 Sep 2012 69

FY 2013 YTD: 165

Oct 2012 97 Nov 2012 29 Dec 2012 39 Jan 2013 Feb 2013 Mar 2013 Apr 2013 May 2013 Jun 2013 Jul 2013 Aug 2013 Sep 2013 http://www.fda.gov/AboutFDA/Transparency/track/ucm206293.htm FDA-TRACK Office of Special Medical Programs Dashboard ਍††਍਍਍਍਍਍਍